Last reviewed · How we verify
NCT03832803
Less to Hold - A Comparison of Bladder Toxicities (Side Effects) in Patients Undergoing Prostate Radiotherapy Between Patients Treated With Empty Bladder and Those on a Drinking Protocol.
NA trial testing Empty bladder in Prostate Cancer in 50 participants. Completed in 25 January 2019.
1 March 2018
Quick facts
| Lead sponsor | Lancashire Teaching Hospitals NHS Foundation Trust |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 50 |
| Start date | 1 March 2017 |
| Primary completion | 1 March 2018 |
| Estimated completion | 25 January 2019 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Empty bladder
- Full bladder
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Radiotherapy Side Effect — all drugs for Radiotherapy Side Effect →
Sponsor
Lancashire Teaching Hospitals NHS Foundation Trust
Who can join
18 and older, male only, with Prostate Cancer or Radiotherapy Side Effect. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Radical radiotherapy to the prostate is conventionally treated with a full bladder with the aim of minimising dose to the bladder and small bowel to prevent significant side effects. Tolerance of the bladder filling protocol varies depending on patients' baseline urinary function. It is not uncommon for some men to have "accidents" during treatment causing understandable distress. This can also extend the treatment time and cause knock on delays in the radiotherapy department. Several United Kingdom (UK) centres report treating with an empty bladder. The investigators carried out a feasibility study comparing treatment with full bladder to empty bladder to ascertain if the investigators can safely change our protocol to that of an empty bladder.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03832803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Lancashire Teaching Hospitals NHS Foundation Trust trials
Trials by the same sponsor.
- NCT06445205 — Utilising Volumetric Absorptive Microsampling (VAMS) Technology to Monitor Tacrolimus and Creatinine · suspended
- NCT06288464 — Enteral Feeding of Fibre to Improve Microbiota · NA · recruiting
- NCT06445985 — Hydrotherapy in Duchenne Muscular Dystrophy (DMD) · NA · active not recruiting
- NCT05686941 — Is Laryngeal Ultrasound Useful in the Assessment for ILO? A Protocol for a Two-stage Exploratory Pilot Study · unknown
- NCT06263920 — Neurofrailty: A Study of Late-onset Epilepsy and Its Associations · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03832803 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lancashire Teaching Hospitals NHS Foundation Trust
- Last refreshed: 6 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03832803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing